Bristol Myers Squibb and SystImmune announced results from the randomized Phase III PANKU-Breast01 trial evaluating iza-bren against chemotherapy in 383 patients with previously treated HR-positive, HER2-negative advanced breast cancer.
Median progression-free survival was 8.2 months versus 4.0 months, corresponding to a hazard ratio of 0.41 (95% CI: 0.33–0.53; p<0.0001). Confirmed objective response rates were 40.5% and 20.2%, respectively.
Overall survival data remain immature. The companies reported predominantly hematologic severe treatment-related adverse events, with adjudicated interstitial lung disease in 1.1% of iza-bren recipients. Bristol Myers Squibb News
Primary source: BMS and SystImmune — October 23 Phase III announcement
Why it matters strategically
Iza-bren is a bispecific ADC targeting EGFR and HER3 and delivering a topoisomerase I inhibitor payload.
The program has now reported positive Phase III results across multiple cancer indications.
However, demonstrating superiority to chemotherapy does not necessarily establish superiority to other ADCs or the most relevant contemporary treatment sequences.
This distinction is important because the competitive environment for HR-positive, HER2-negative metastatic breast cancer has changed considerably.
A treatment may demonstrate substantial clinical benefit in a randomized trial while still facing uncertainty regarding its eventual positioning against established and emerging therapies.
